Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemirciclib + Acalabrutinib in Advanced Hematological Malignancies
NCT04630756Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of zemirciclib in diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), sponsored by AstraZeneca. Primary endpoints: Number of Participants With Adverse Events and Overall Response Rate. Started Feb 2021; status: completed.
02
Drugs
zemirciclib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)marginal zone lymphoma (MZL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04630756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630756.